Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution
Myriad Genetics, Inc. (MYGN)
Last myriad genetics, inc. earnings: 2/6 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
myriad.com/news-center/investor-information
Company Research
Source: GlobeNewswire
Highlights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million.Full year 2025 revenue of $824.5 million decreased 2% year-over-year. Excluding headwinds2, full year 2025 revenue grew 2% year-over-year. Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12%, Hereditary cancer testing at 9%, and GeneSight at 9%. Fourth quarter 2025 gross margin was 70.0% and in-line with third quarter 2025. Fourth quarter 2025 GAAP net loss of $7.9 million, or $0.08 per share, while adjusted EPS was $0.04 per share and adjusted EBITDA was $14.3 million. SALT LAKE CITY, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its fourth quarter ended December 31, 2025, and reaffirmed its financial
Show less
Read more
Impact Snapshot
Event Time:
MYGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MYGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MYGN alerts
High impacting Myriad Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
MYGN
News
- Why Myriad Genetics (MYGN) Stock Is Trading Up Today [Yahoo! Finance]Yahoo! Finance
- Myriad Genetics (NASDAQ:MYGN) had its price target lowered by analysts at Wells Fargo & Company from $6.50 to $6.00. They now have an "equal weight" rating on the stock.MarketBeat
- Myriad Genetics (NASDAQ:MYGN) had its "neutral" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk testsGlobeNewswire
- Myriad Genetics Inc (MYGN) Q4 2025 Earnings Call Highlights: Surpassing Revenue Expectations ... [Yahoo! Finance]Yahoo! Finance
MYGN
Earnings
- 2/23/26 - Beat
MYGN
Sec Filings
- 2/24/26 - Form S-3
- 2/24/26 - Form 10-K
- 2/23/26 - Form 8-K
- MYGN's page on the SEC website